Stock Research: Kobayashi Pharmaceutical

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Kobayashi Pharmaceutical

TSE:4967 JP3301100008
53
  • Value
    88
  • Growth
    87
  • Safety
    Safety
    11
  • Combined
    74
  • Sentiment
    26
  • 360° View
    360° View
    53
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

KOBAYASHI PHARMACEUTICAL CO., LTD. is a drug manufacturer that offers health care, daily necessities, skin care, dietary supplements, and other products through its Domestic Household Products Manufacturing and Sales, Overseas Household Products Manufacturing and Sales, and Mail Order segments. In the last fiscal year, the company had a market cap of $2716 million, profits of $557 million, revenue of $1054 million, and 3615 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 53 (better than 53% compared with alternatives), overall professional sentiment and financial characteristics for the stock Kobayashi Pharmaceutical are above average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Kobayashi Pharmaceutical. The consolidated Growth Rank has a good rank of 87, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 87% of competitors in the same industry. In addition, the consolidated Safety Rank has a safer rank of 88 which means that the company has a financing structure that is safer than 88% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the consolidated Value Rank has a less desirable rank of 11 which means that the share price of Kobayashi Pharmaceutical is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is higher than for 89% of alternative stocks in the same industry. The consolidated Sentiment Rank also has a low rank of 26, which means that professional investors are more pessimistic about the stock than for 74% of alternative investment opportunities. ...read more

more
Index
SDG 12
SDG 13
SDG 3
SDG 5
SDG 8
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
11 19 18 7
Growth
87 44 37 37
Safety
Safety
88 75 92 83
Sentiment
26 15 63 30
360° View
360° View
53 27 42 17
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
26 25 41 29
Opinions Change
42 40 83 50
Pro Holdings
n/a 27 72 42
Market Pulse
9 5 38 51
Sentiment
26 15 63 30
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
11 19 18 7
Growth
87 44 37 37
Safety Safety
88 75 92 83
Combined
74 44 33 32
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
19 26 34 23
Price vs. Earnings (P/E)
21 23 22 19
Price vs. Book (P/B)
37 36 38 22
Dividend Yield
46 49 44 18
Value
11 19 18 7
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
50 43 28 32
Profit Growth
73 71 35 45
Capital Growth
75 7 75 82
Stock Returns
73 57 23 23
Growth
87 44 37 37
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
94 97 94 88
Refinancing
45 44 61 53
Liquidity
94 82 94 90
Safety Safety
88 75 92 83

Similar Stocks

Discover high‑ranked alternatives to Kobayashi Pharmaceutical and broaden your portfolio horizons.

Japan Airlines

TSE:9201
Country: Japan
Industry: Airlines
Size: X-Large
Full Stock Analysis

Megmilk Snow Brand

TSE:2270
Country: Japan
Industry: Packaged Foods & Meats
Size: Medium
Full Stock Analysis

Tokuyama

TSE:4043
Country: Japan
Industry: Specialty Chemicals
Size: Medium
Full Stock Analysis

Daicel

TSE:4202
Country: Japan
Industry: Diversified Chemicals
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.